| 1 |
34140638 | Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. | 2021 Aug |
2 |
| 2 |
27871087 | The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. | 2018 |
2 |
| 3 |
30217415 | In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. | 2018 Nov 1 |
1 |
| 4 |
27507190 | Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. | 2016 Jun 7 |
1 |
| 5 |
25965177 | A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. | 2015 May 12 |
2 |
| 6 |
26206331 | Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. | 2015 Oct |
4 |